Effect of short-term treatment with low dosages of the proton-pump inhibitor omeprazole on serum chromogranin A levels in man
| Autor: | Marilena Sidoti, Massimo Giusti, Francesco Minuto, Carla Rabitti, Clara Augeri |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2004 |
| Předmět: |
Adult
Male endocrine system medicine.medical_specialty Dose Adolescent medicine.drug_class Endocrinology Diabetes and Metabolism Proton-pump inhibitor Neuroendocrine tumors chemistry.chemical_compound Endocrinology Internal medicine medicine Biomarkers Tumor Chromogranins Endocrine system Humans Enzyme Inhibitors Omeprazole Gastrin Aged Aged 80 and over Creatinine biology business.industry Chromogranin A Proton Pump Inhibitors General Medicine Middle Aged medicine.disease Neuroendocrine Tumors chemistry biology.protein Female business medicine.drug |
| Popis: | BACKGROUND: Measurement of chromogranin A (CgA) levels in blood can be used to monitor neuroendocrine tumors (NETs). CgA levels may also be elevated in several other endocrine and non-endocrine diseases. It is well known that drugs affecting acid gastric secretion can increase gastrin. Proton-pump inhibitors are extensively used but only a few data have been reported on their effects on CgA secretion. DESIGN: The aim of the study was to evaluate the short-term effect of low dosages of omeprazole (OM) on CgA levels and to sensitize endocrinologists to possible false positive values of CgA in order to prevent expensive diagnostic work-up in searching for NETs. SUBJECTS AND METHODS: Thirty-five female and nine male in-patients (18-81 years) were studied. Mild or severe hypertension in 20 patients needed therapy. Endocrine and metabolic diseases were diagnosed in the majority of patients. CgA levels were evaluated before and during OM therapy (10 mg/day, orally). RESULTS: Without OM therapy, CgA levels were 64+/-6 microg/l. Elevated baseline CgA levels were found in nine subjects. CgA levels were significantly related to age (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|